Show simple item record

dc.contributor.authorIngimarsson, Oddur
dc.contributor.authorMacCabe, James H
dc.contributor.authorHaraldsson, Magnús
dc.contributor.authorJónsdóttir, Halldóra
dc.contributor.authorSigurdsson, Engilbert
dc.date.accessioned2016-08-04T14:45:15Z
dc.date.available2016-08-04T14:45:15Z
dc.date.issued2016-08
dc.date.submitted2016
dc.identifier.citationClozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records. 2016, 70 (6):450-5 Nord J Psychiatryen
dc.identifier.issn1502-4725
dc.identifier.pmid27049594
dc.identifier.doi10.3109/08039488.2016.1155234
dc.identifier.urihttp://hdl.handle.net/2336/617944
dc.descriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.en
dc.description.abstractClozapine is the only drug approved for treatment-resistant schizophrenia. There is evidence that clozapine is underutilized.
dc.description.abstractTo evaluate the initiation and discontinuation of clozapine at Landspitali University Hospital in Iceland and the prevalence of antipsychotic polypharmacy in clozapine-treated patients.
dc.description.abstractThe study is a part of an ongoing longitudinal study of schizophrenia in Iceland. We identified 201 patients on clozapine or who have been on clozapine by using a keyword search in the electronic health records and by reviewing their medical records.
dc.description.abstractMean age at first treatment with clozapine was 37.8 years. Mean follow-up period on clozapine was 11 years. After 20 years of treatment 71.2% of patients were still on clozapine. After one year of treatment 84.4% of patients were still receiving clozapine treatment. We estimate that 11.4% of patients with schizophrenia in Iceland are taking clozapine and that 16% have been treated with clozapine at some point. Polypharmacy is common, since nearly 2/3, 65.6%, of patients taking clozapine use at least one other antipsychotic and 16.9% are also receiving depot injections.
dc.description.abstractWe need to increase the awareness of psychiatrists in Iceland with regard to treatment with clozapine, since only about half of the estimated population of patients with treatment-resistant schizophrenia in Iceland have ever been treated with clozapine. Nearly two thirds of patients who are prescribed clozapine in Iceland remain on it long-term.
dc.description.sponsorshipinfo:eu-repo/grantAgreement/EC/FP7/279227 National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College Londonen
dc.language.isoenen
dc.publisherTaylor & Francis Ltden
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/279227en
dc.relation.urlhttp://dx.doi.org/ 10.3109/08039488.2016.1155234en
dc.rightsopenAccessen
dc.subjectPSY12
dc.subject.meshAntipsychotic Agentsen
dc.subject.meshClozapineen
dc.subject.meshPolypharmacyen
dc.subject.meshSchizophreniaen
dc.titleClozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records.en
dc.typearticleen
dc.contributor.department[ 1 ] Univ Iceland, Sch Hlth Sci, Fac Med, Reykjavik, Iceland [ 2 ] Landspitali Univ Hosp, Mental Hlth Serv, IS-101 Reykjavik, Iceland   Organization-Enhanced Name(s)      Landspitali National University Hospital [ 3 ] Kings Coll London, London WC2R 2LS, England [ 4 ] South London & Maudsley NHS Fdn Trust, Bethlem Royal Hosp, Natl Psychosis Unit, London, Englanden
dc.identifier.journalNordic journal of psychiatryen
dc.rights.accessOpen Accessen
refterms.dateFOA2018-09-12T16:07:11Z
html.description.abstractClozapine is the only drug approved for treatment-resistant schizophrenia. There is evidence that clozapine is underutilized.
html.description.abstractTo evaluate the initiation and discontinuation of clozapine at Landspitali University Hospital in Iceland and the prevalence of antipsychotic polypharmacy in clozapine-treated patients.
html.description.abstractThe study is a part of an ongoing longitudinal study of schizophrenia in Iceland. We identified 201 patients on clozapine or who have been on clozapine by using a keyword search in the electronic health records and by reviewing their medical records.
html.description.abstractMean age at first treatment with clozapine was 37.8 years. Mean follow-up period on clozapine was 11 years. After 20 years of treatment 71.2% of patients were still on clozapine. After one year of treatment 84.4% of patients were still receiving clozapine treatment. We estimate that 11.4% of patients with schizophrenia in Iceland are taking clozapine and that 16% have been treated with clozapine at some point. Polypharmacy is common, since nearly 2/3, 65.6%, of patients taking clozapine use at least one other antipsychotic and 16.9% are also receiving depot injections.
html.description.abstractWe need to increase the awareness of psychiatrists in Iceland with regard to treatment with clozapine, since only about half of the estimated population of patients with treatment-resistant schizophrenia in Iceland have ever been treated with clozapine. Nearly two thirds of patients who are prescribed clozapine in Iceland remain on it long-term.


Files in this item

Thumbnail
Name:
Clozapine_16.pdf
Size:
925.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record